Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: WTDEC who wrote (21919)	6/6/1998 2:01:00 AM
From: bob zagorin	Read Replies (2) \| Respond to of 32384

interesting article in new red herring on why protein research is more important than discovering the genome. >Freeman Dyson on biotech< redherring.com BOP dropped way back yellow today just above neutral but volume was light.

To: WTDEC who wrote (21919)	6/6/1998 8:21:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

W, An interferon agonist program has been listed by LGND for several years (see home.att.net ), but I had thought that the transcription factors (back end of the pathway)were being targeted, not the interferon receptor (front end of the pathway). Are you referring to the former or latter? If they were talking about a mimic in the same sense as the G-CSF mimic, then it would be the front end and would given them an even stronger patent position (as well as leadership in a newly defined field).